 Antibodies, Monoclonal
"Antibodies, Monoclonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies produced by a single clone of cells.
| Descriptor ID |
D000911
|
| MeSH Number(s) |
D12.776.124.486.485.114.224 D12.776.124.790.651.114.224 D12.776.377.715.548.114.224
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal".
This graph shows the total number of publications written about "Antibodies, Monoclonal" by people in this website by year, and whether "Antibodies, Monoclonal" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 5 | 12 | 17 | | 1997 | 5 | 5 | 10 | | 1998 | 2 | 14 | 16 | | 1999 | 7 | 7 | 14 | | 2000 | 7 | 9 | 16 | | 2001 | 11 | 16 | 27 | | 2002 | 7 | 17 | 24 | | 2003 | 8 | 11 | 19 | | 2004 | 12 | 17 | 29 | | 2005 | 16 | 14 | 30 | | 2006 | 18 | 14 | 32 | | 2007 | 22 | 11 | 33 | | 2008 | 12 | 19 | 31 | | 2009 | 35 | 20 | 55 | | 2010 | 28 | 23 | 51 | | 2011 | 15 | 17 | 32 | | 2012 | 12 | 14 | 26 | | 2013 | 15 | 8 | 23 | | 2014 | 33 | 9 | 42 | | 2015 | 11 | 10 | 21 | | 2016 | 17 | 13 | 30 | | 2017 | 25 | 16 | 41 | | 2018 | 21 | 10 | 31 | | 2019 | 19 | 9 | 28 | | 2020 | 27 | 12 | 39 | | 2021 | 18 | 9 | 27 | | 2022 | 6 | 25 | 31 | | 2023 | 5 | 19 | 24 | | 2024 | 14 | 14 | 28 | | 2025 | 24 | 7 | 31 | | 2026 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
Cliff ERS, Pelaez GD, Wan F, Iyengar V, Zhou J, Chung K, Abdel-Razeq N, Allen J, Major A, Sharp J, Epperla N, Gould P, Cherng HJ, Houshyar S, Wallace DS, Lynch RC, Kallam A, Mei MG, Merryman RW, Fleyshman M, Rhodes JM, Kidwell A, Fenske TS, Malakhov N, Mulvey E, Watkins MP, Alhaj Moustafa M, Hilal T, Nowakowski GS, Wang Y, Torka P, Russler-Germain DA. Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma. Clin Cancer Res. 2026 Jan 06; 32(1):159-168.
-
Patil T, Lin JJ, Cheema PK, Carrizosa DR, Burkard ME, Elamin YY, Desai J, Patel JD, Nagasaka M, Reckamp KL, Waqar SN, Bauman JR, Schram AM, Gadgeel SM, Ma PC, Konduri K, Nguyen D, Misleh J, Bleeker J, Weiss M, Thavaneswaran S, Haura EB, Deegan M, Kaufman J, Srivastava J, Jansen VM, Liu SV. CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions. JCO Precis Oncol. 2025 Aug; 9:e2500221.
-
Muthuraman K, Jackman M, Liang Y, Garrett ME, Cui H, Nguyen LVH, Ivanochko D, Ye C, Pino PA, Hicks A, Maingot B, Yusko E, Benzeno S, MartÃnez-Sobrido L, Torrelles JB, Gilbert AE, Rubin BER, Keitany G, Jetha A, Julien J-P. Human antibody targeting of coronavirus spike S2 subunit is associated with protection mediated by Fc effector functions. J Virol. 2025 12 23; 99(12):e0152325.
-
Wynne C, Lorch U, Krantz E, Katial R, Ashdown T, Luque M, Sattar A, Rai M, Vashishta L, Petrovic K, Ruffieux R, Leutz S, Berti F. Pharmacokinetic Similarity of Biosimiliar AVT05 Versus Reference Product Golimumab in Healthy Adults: A Double-Blind, Three-Arm, Parallel-Group Study. BioDrugs. 2026 Jan; 40(1):121-133.
-
Ho AWS, Fukuzawa T, Koga H, Ohmine K, Kawauchi H, Muraoka M, Ikuta Y, Gupta G, Okuda M, Onami I, Ayabe M, Takeiri A, Konishi H, Sugawara Y, Usami S, Ito E, Shibahara N, Ozeki K, Wada Y, Hirako A, Takahashi N, Sampei Z, Haraya K, Murao N, Fujii T, Torizawa T, Shimada H, Igawa T. Long lasting complement neutralisation by RAY121, an engineered anti-C1s antibody with C1q displacement function. EBioMedicine. 2025 Dec; 122:106009.
-
DuBois SG, Moreno L, Bagatell R, Cheung NK, Gray JC, Locatelli F, Reynolds CP, Rossig C, Sondel PM, Drezner N, Kholmanshikh O, Bird N, Day L, Ludwinski D, Scobie N, Pons Sanz V, Ball S, Hammer B, Alvarez Rojo I, Meager D, Sveistrup J, Berlanga P, Casanova M, Glade-Bender J, Macy M, Morgenstern DA, Owens C, Weigel BJ, Pappo A, Nysom K, Anderson J, Ligas F, Lesa G, Donoghue M, Karres D, Vassal G. Paediatric Strategy Forum for medicinal product development of agents targeting GD2 ganglioside in children and adolescents with cancer. Eur J Cancer. 2025 Dec 09; 231:116093.
-
Lucas A, Bespalova A, Upadhyay V, Monroe L, Chetcuti M, Callegari C, Tripathi DK, Bain DL, Martini A, Vico A, Mallela KMG. Synergistic effect of plunger insertion and siliconization methods on particle formation of an antibody formulation. J Pharm Sci. 2025 Dec; 114(12):104032.
-
Balakrishnan I, Madhavan K, Pierce A, Michlin J, Brunt B, Lakshmanachetty S, Wang D, DeSisto J, Nuss ZJ, Davidson N, Walker F, Suresh A, Donson A, Sanford B, Jones KL, Danis EP, Mitra SS, Green AL, Dahl N, Vibhakar R, Venkataraman S. Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma. Cancer Res. 2025 Aug 15; 85(16):3089-3110.
-
Sun Y, Fujiwara Y, Torphy RJ, Yee EJ, Guo Y, Sun Z, Hu J, Eck E, Terai T, Schulick RD, Zhu Y. CD93 blockade overcomes sunitinib resistance in pancreatic neuroendocrine tumors. Mol Ther. 2025 Oct 01; 33(10):5017-5027.
-
Muro K, Feinstein T, Baranda J, Bonta I, Yanagitani N, Gersten T, Gandhi L, Kudo T, Fujioka N, Kaplan J, Gorla S, Liu S, Wozniak M, Poondru S, Dillon R, Meng C, Patil T. Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study. Eur J Cancer. 2025 Sep 09; 227:115603.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|